Cargando…
Expression profile of Oct-4 lung cancer-specific marker prior and subsequent to a salirasib treatment regime
Lung cancer is one of the leading types of cancer that lead to mortalities in the male and female populations. The existing lung cancer-specific markers are not able to accurately predict the condition of the disease, and the response of these markers can vary under various pathological conditions....
Autores principales: | Ao, Xiang, Zhou, Jie, Liang, Hong Ling, Jiang, Ming, Li, Hong Sheng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5666668/ https://www.ncbi.nlm.nih.gov/pubmed/29142598 http://dx.doi.org/10.3892/ol.2017.6868 |
Ejemplares similares
-
Celecoxib combined with salirasib strongly inhibits pancreatic cancer cells in 2D and 3D cultures
por: Li, Dongli, et al.
Publicado: (2020) -
Salirasib sensitizes hepatocarcinoma cells to TRAIL-induced apoptosis through DR5 and survivin-dependent mechanisms
por: Charette, N, et al.
Publicado: (2013) -
Growth of poorly differentiated endometrial carcinoma is inhibited by combined action of medroxyprogesterone acetate and the Ras inhibitor Salirasib
por: Faigenbaum, Raya, et al.
Publicado: (2013) -
An early clinical trial of Salirasib, an oral RAS inhibitor, in Japanese patients with relapsed/refractory solid tumors
por: Furuse, Junji, et al.
Publicado: (2018) -
Computer-Based Identification of a Novel LIMK1/2 Inhibitor that Synergizes with Salirasib to Destabilize the Actin Cytoskeleton
por: Mashiach-Farkash, Efrat, et al.
Publicado: (2012)